查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1397026

大環內酯類抗生素市場：按藥物類型、給藥途徑、適應症、配銷通路：全球機會分析和產業預測，2023-2032

Macrolide Antibiotics Market By Drug Type, By Route of Administration, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 306 Pages | 商品交期: 2-3個工作天內

價格

2022年大環內酯類抗生素市值為56億美元，預計2032年將達70億美元，2023年至2032年的年複合成長率為2.3%。

大環內酯類是一種用於治療和控制細菌感染的抗生素。這些抗生素化合物具有連接到大環內酯環上的脫氧糖。紅黴素是1952年開發的第一種大環內酯類抗生素，用於治療對青黴素過敏和青黴素抗藥性的感染疾病患者。其他大環內酯類抗生素包括羅紅黴素、克拉黴素、泰利黴素、阿奇黴素和非達黴素。 FDA已核准使用這些抗生素來治療各種細菌感染疾病，增加了其市場需求。

大環內酯類抗生素透過抑制細菌蛋白質合成發揮作用。這些化合物與細菌 50S 核醣體次單元結合並關閉細菌蛋白質合成。結合後，它會阻止肽基轉移酶向 tRNA付加胺基酸，從而抑制 mRNA 翻譯。紅黴素是最常用的抗生素，其次是阿奇黴素和克拉黴素。其他抗生素對許多細菌菌株有活性，包括鏈球菌、葡萄球菌、梭狀芽胞桿菌、棒狀桿菌、李斯特菌和嗜血桿菌。紅黴素的活性譜較窄，作用於革蘭氏陽性菌和少數革蘭氏陰性菌。另一方面，克拉黴素和阿奇黴素對幽門螺旋桿菌和弓形蟲等革蘭氏陰性菌有效。

全球細菌感染疾病數量的增加是推動大環內酯類抗生素市場成長的主要因素。皮膚感染疾病、呼吸道感染疾病和性傳染感染疾病等細菌性疾病的盛行率很高。例如，根據世界衛生組織估計，2020 年成人淋病新發病例估計為 8,240 萬例。淋病是一種常見的性行為感染，在性工作者、跨性別女性和青少年中患病率最高。因此，此類感染疾病的增加正在推動對大環內酯類抗生素的需求並促進市場成長。

然而，細菌種類之間不斷增加的抗菌素抗藥性正在阻礙市場成長。大環內酯類抗藥性細菌的出現使得嚴重感染疾病的治療變得困難，可能導致患者死亡、住院時間延長和治療費用增加。隨著大環內酯類抗藥性細菌引起的感染疾病增加，治療效果會降低，可用的大環內酯類藥物的用量也會減少。這可能會阻礙大環內酯類抗生素市場的成長。

然而，細菌對大環內酯類藥物抗藥性的上升預計將為預測期內的市場成長提供有利的機會。隨著細菌對現有的大環內酯類抗生素產生抗藥性，越來越需要克服抗藥性並開發可有效治療嚴重細菌感染疾病。為此，與大環內酯類抗生素相關的研發活動不斷增加，預計未來幾年將為市場成長提供良好的機會。

相關人員的主要利益

  • 該報告提供了細分市場、當前趨勢、估計和動態，並確定了大環內酯類抗生素市場有前景的市場機會。
  • 我們提供市場研究以及與市場促進因素、市場抑制因素和市場機會相關的資訊。
  • 波特的五力分析揭示了買家和供應商的潛力，幫助相關人員做出利潤驅動的業務決策並加強供應商和買家網路。
  • 大環內酯類抗生素市場細分的詳細分析有助於識別市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並提供對市場參與者當前位置的清晰了解。
  • 該報告包括對區域和全球大環內酯類抗生素市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

其他好處包括：

  • 季度資訊和*（僅適用於公司許可證。）在購買之前或之後免費更新您選擇的 5 個其他公司簡介。
  • 如果您購買 5 使用者許可證或企業使用者許可證，將免費提供下一個版本。
  • 16 小時分析師支援*（購買後，如果您的報告審查發現有額外的資料要求，您將獲得 16 小時分析師支持，以解決任何問題或售後聯絡方式。）
  • 15% 免費自訂*（如果報告的範圍或部分不符合您的要求，15% 相當於 3 個工作日的免費工作。）
  • 5 個用戶許可證和企業用戶許可證的免費資料包。 （Excel版報告）
  • 如果您的報告超過 6-12 個月，我們將免費提供更新的報告。
  • 24 小時優先回應*。
  • 免費業界資訊和白皮書

該報告可以客製化（需要單獨的費用和時間表）。

  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • 主要參與者的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 細菌感染疾病增加
      • 學名藥的可得性
      • 新興國家對大環內酯類藥物的龐大需求
    • 抑制因素
      • 抗菌素抗藥性增加
      • 大環內酯類抗生素相關的副作用
    • 機會
      • 加大研發投入

第4章大環內酯類抗生素市場：依藥物類型

  • 概述
  • 阿奇黴素
  • 紅黴素
  • 其他

第5章大環內酯類抗生素市場：依給藥途徑

  • 概述
  • 口服劑
  • 胃腸外的
  • 其他

第6章大環內酯類抗生素市場：依適應症分類

  • 概述
  • 呼吸道感染疾病
  • 皮膚感染疾病
  • 性行為感染傳染病
  • 胃腸道感染疾病
  • 其他

第7章大環內酯類抗生素市場：依配銷通路

  • 概述
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第8章大環內酯類抗生素市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第9章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第10章 公司簡介

  • Abbott Laboratories
  • Pfizer Inc.
  • Alkem Laboratories Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Wellona Pharma Private Limited.
  • Bristol Laboratories Ltd.
  • Crescent Pharma Limited
  • Merck & Co., Inc.
  • Zydus Lifesciences Limited
Product Code: A69591

The macrolide antibiotics market was valued at $5.6 billion in 2022 and is estimated to reach $7.0 billion by 2032, exhibiting a CAGR of 2.3% from 2023 to 2032. Macrolides are a class of antibiotics, used to treat and manage bacterial infections. These antibiotic compounds have a macrocyclic lactone ring attached with deoxy sugars. Erythromycin was the first macrolide antibiotic developed in 1952 and was used in the treatment of infections in patients allergic to penicillin and also in the case of penicillin resistant infections. Other macrolide antibiotics include roxithromycin, clarithromycin, telithromycin, azithromycin, fidaxomicin and others. The FDA has approved the use of these antibiotics in the treatment of various bacterial infections, which increases their demand in the market.

Macrolide antibiotics act by inhibiting bacterial protein synthesis. These compounds bind to the bacterial 50 S ribosomal subunit, causing the cessation of bacterial protein synthesis. After binding, the drug prevents the translation of mRNA, by inhibiting the enzyme peptidyl transferase from adding the subsequent amino acid attached to the tRNA. Erythromycin is the most used antibiotic, followed by azithromycin and clarithromycin. These antibiotics are active against many strains of bacteria such as streptococci, staphylococci, clostridia, corynebacteria, listeria, haemoplhillus, and others. Erythromycin has a narrow spectrum of activity with action against gram-positive and few gram-negative bacteria. On the other hand, clarithromycin and azithromycin are active against gram-negative bacteria such as helicobacter pylori, taxoplasma gondii and others.

Rise in incidences of bacterial infections around the globe is the major factor driving the growth of the macrolide antibiotics market. There is a significant prevalence of bacterial diseases such as skin infections, respiratory tract infections, sextually transmitted bacterial infection, and others. For instance, according to the WHO, there were an estimated 82.4 million new gonorrhoea infections among adults in 2020. Gonorrhoea is a common sexually transmitted infection having the highest incidence among sex workers, transgender women and adolescents. Thus, rise in incidences of such infections boost the demand for macrolide antibiotics, which contributes to the market growth.

However, rise in antimicrobial resistance among the bacterial species causes hindrance to the market growth. Emergence of macrolide resistant bacteria causes difficulty in treatment of severe infections, which may lead to the death of the patient, increase hospital stay, and increase the cost and expenses related to treatment. As the number of infections caused by macrolide resistant bacteria increases, drugs become ineffective for treatment and thus, there is a reduction in use of available macrolide medications. . This may hinder the growth of the macrolide antibiotics market.

However, a rise in antimicrobial resistance for macrolide class of drug is expected to offer lucrative opportunities for market growth during the forecast period. As bacteria are resistant to the available macrolide antibiotics, there is rise in demand for development of new novel macrolide antibiotics that may help overcome the resistance and thus, are effective in the treatment of severe bacterial infections. This increases R&D activities related to the macrolides and thus, is expected to offer lucrative opportunities for market growth in the coming years.

The macrolide antibiotics market is segmented on the basis of drug type, route or administration, indication, distribution channel, and region. On the basis of drug type, the market is segmented into azithromycin, erythromycin, and others. On the basis of route of administration, the market is classified into oral, parenteral, and others. By indication, the market is segmented into respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers.

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of AsiaPacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited.

  • Key Benefits for Stakeholders
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the macrolide antibiotics market analysis from 2022 to 2032 to identify the prevailing macrolide antibiotics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the macrolide antibiotics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global macrolide antibiotics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Type

  • Azithromycin
  • Erythromycin
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Indication

  • Respiratory Tract Infections
  • Skin Infections
  • Sexually Transmitted Infections
  • Gastrointestinal Infections
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
    • Wellona Pharma Private Limited.
    • Sun Pharmaceutical Industries Limited
    • Bristol Laboratories Ltd.
    • Zydus Lifesciences Limited
    • Alkem Laboratories Ltd.
    • Crescent Pharma Limited
    • Merck & Co., Inc.
    • Abbott Laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidences of bacterial infections
      • 3.4.1.2. Availability of generic medications
      • 3.4.1.3. Significant demand for macrolides from emerging countries
    • 3.4.2. Restraints
      • 3.4.2.1. Rise in antimicrobial resistance
      • 3.4.2.2. Side effects associated with macrolide antibiotics
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in investments in research and development activities

CHAPTER 4: MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Azithromycin
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Erythromycin
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Parenteral
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: MACROLIDE ANTIBIOTICS MARKET, BY INDICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Respiratory Tract Infections
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Skin Infections
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Sexually Transmitted Infections
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Gastrointestinal Infections
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country
  • 6.6. Others
    • 6.6.1. Key market trends, growth factors and opportunities
    • 6.6.2. Market size and forecast, by region
    • 6.6.3. Market share analysis by country

CHAPTER 7: MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Drug Stores and Retail Pharmacies
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Online Providers
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: MACROLIDE ANTIBIOTICS MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Drug Type
    • 8.2.3. Market size and forecast, by Route of Administration
    • 8.2.4. Market size and forecast, by Indication
    • 8.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Drug Type
      • 8.2.6.1.2. Market size and forecast, by Route of Administration
      • 8.2.6.1.3. Market size and forecast, by Indication
      • 8.2.6.1.4. Market size and forecast, by Distribution Channel
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Drug Type
      • 8.2.6.2.2. Market size and forecast, by Route of Administration
      • 8.2.6.2.3. Market size and forecast, by Indication
      • 8.2.6.2.4. Market size and forecast, by Distribution Channel
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Drug Type
      • 8.2.6.3.2. Market size and forecast, by Route of Administration
      • 8.2.6.3.3. Market size and forecast, by Indication
      • 8.2.6.3.4. Market size and forecast, by Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Drug Type
    • 8.3.3. Market size and forecast, by Route of Administration
    • 8.3.4. Market size and forecast, by Indication
    • 8.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Drug Type
      • 8.3.6.1.2. Market size and forecast, by Route of Administration
      • 8.3.6.1.3. Market size and forecast, by Indication
      • 8.3.6.1.4. Market size and forecast, by Distribution Channel
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Drug Type
      • 8.3.6.2.2. Market size and forecast, by Route of Administration
      • 8.3.6.2.3. Market size and forecast, by Indication
      • 8.3.6.2.4. Market size and forecast, by Distribution Channel
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Drug Type
      • 8.3.6.3.2. Market size and forecast, by Route of Administration
      • 8.3.6.3.3. Market size and forecast, by Indication
      • 8.3.6.3.4. Market size and forecast, by Distribution Channel
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Drug Type
      • 8.3.6.4.2. Market size and forecast, by Route of Administration
      • 8.3.6.4.3. Market size and forecast, by Indication
      • 8.3.6.4.4. Market size and forecast, by Distribution Channel
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Drug Type
      • 8.3.6.5.2. Market size and forecast, by Route of Administration
      • 8.3.6.5.3. Market size and forecast, by Indication
      • 8.3.6.5.4. Market size and forecast, by Distribution Channel
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Drug Type
      • 8.3.6.6.2. Market size and forecast, by Route of Administration
      • 8.3.6.6.3. Market size and forecast, by Indication
      • 8.3.6.6.4. Market size and forecast, by Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Drug Type
    • 8.4.3. Market size and forecast, by Route of Administration
    • 8.4.4. Market size and forecast, by Indication
    • 8.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Drug Type
      • 8.4.6.1.2. Market size and forecast, by Route of Administration
      • 8.4.6.1.3. Market size and forecast, by Indication
      • 8.4.6.1.4. Market size and forecast, by Distribution Channel
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Drug Type
      • 8.4.6.2.2. Market size and forecast, by Route of Administration
      • 8.4.6.2.3. Market size and forecast, by Indication
      • 8.4.6.2.4. Market size and forecast, by Distribution Channel
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by Drug Type
      • 8.4.6.3.2. Market size and forecast, by Route of Administration
      • 8.4.6.3.3. Market size and forecast, by Indication
      • 8.4.6.3.4. Market size and forecast, by Distribution Channel
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by Drug Type
      • 8.4.6.4.2. Market size and forecast, by Route of Administration
      • 8.4.6.4.3. Market size and forecast, by Indication
      • 8.4.6.4.4. Market size and forecast, by Distribution Channel
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Drug Type
      • 8.4.6.5.2. Market size and forecast, by Route of Administration
      • 8.4.6.5.3. Market size and forecast, by Indication
      • 8.4.6.5.4. Market size and forecast, by Distribution Channel
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Drug Type
      • 8.4.6.6.2. Market size and forecast, by Route of Administration
      • 8.4.6.6.3. Market size and forecast, by Indication
      • 8.4.6.6.4. Market size and forecast, by Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Drug Type
    • 8.5.3. Market size and forecast, by Route of Administration
    • 8.5.4. Market size and forecast, by Indication
    • 8.5.5. Market size and forecast, by Distribution Channel
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by Drug Type
      • 8.5.6.1.2. Market size and forecast, by Route of Administration
      • 8.5.6.1.3. Market size and forecast, by Indication
      • 8.5.6.1.4. Market size and forecast, by Distribution Channel
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Market size and forecast, by Drug Type
      • 8.5.6.2.2. Market size and forecast, by Route of Administration
      • 8.5.6.2.3. Market size and forecast, by Indication
      • 8.5.6.2.4. Market size and forecast, by Distribution Channel
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Market size and forecast, by Drug Type
      • 8.5.6.3.2. Market size and forecast, by Route of Administration
      • 8.5.6.3.3. Market size and forecast, by Indication
      • 8.5.6.3.4. Market size and forecast, by Distribution Channel
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Market size and forecast, by Drug Type
      • 8.5.6.4.2. Market size and forecast, by Route of Administration
      • 8.5.6.4.3. Market size and forecast, by Indication
      • 8.5.6.4.4. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Abbott Laboratories
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
  • 10.2. Pfizer Inc.
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
  • 10.3. Alkem Laboratories Ltd.
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
  • 10.4. Sun Pharmaceutical Industries Limited
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Teva Pharmaceutical Industries Limited
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
    • 10.5.7. Key strategic moves and developments
  • 10.6. Wellona Pharma Private Limited.
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
  • 10.7. Bristol Laboratories Ltd.
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
  • 10.8. Crescent Pharma Limited
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
  • 10.9. Merck & Co., Inc.
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
    • 10.9.7. Key strategic moves and developments
  • 10.10. Zydus Lifesciences Limited
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. MACROLIDE ANTIBIOTICS MARKET FOR AZITHROMYCIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MACROLIDE ANTIBIOTICS MARKET FOR ERYTHROMYCIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 06. MACROLIDE ANTIBIOTICS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. MACROLIDE ANTIBIOTICS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 10. MACROLIDE ANTIBIOTICS MARKET FOR RESPIRATORY TRACT INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. MACROLIDE ANTIBIOTICS MARKET FOR SKIN INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. MACROLIDE ANTIBIOTICS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. MACROLIDE ANTIBIOTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. MACROLIDE ANTIBIOTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. MACROLIDE ANTIBIOTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. MACROLIDE ANTIBIOTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. MACROLIDE ANTIBIOTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 25. U.S. MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. U.S. MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 28. U.S. MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. CANADA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 31. CANADA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 32. CANADA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. UK MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 51. UK MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. UK MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 53. UK MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. ITALY MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 55. ITALY MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. ITALY MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 57. ITALY MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 72. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 74. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. CHINA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 76. CHINA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. CHINA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 78. CHINA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. INDIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 81. INDIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 82. INDIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 84. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 85. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 86. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 94. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 98. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 101. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 102. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 103. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 107. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 108. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 109. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 110. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 111. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 112. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 113. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 116. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 117. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 118. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 119. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 120. PFIZER INC.: KEY EXECUTIVES
  • TABLE 121. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 122. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 123. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 124. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 125. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 126. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 127. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 131. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 132. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 133. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 134. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 135. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 136. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 137. WELLONA PHARMA PRIVATE LIMITED.: KEY EXECUTIVES
  • TABLE 138. WELLONA PHARMA PRIVATE LIMITED.: COMPANY SNAPSHOT
  • TABLE 139. WELLONA PHARMA PRIVATE LIMITED.: PRODUCT SEGMENTS
  • TABLE 140. WELLONA PHARMA PRIVATE LIMITED.: PRODUCT PORTFOLIO
  • TABLE 141. BRISTOL LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 142. BRISTOL LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 143. BRISTOL LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 144. BRISTOL LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 145. CRESCENT PHARMA LIMITED: KEY EXECUTIVES
  • TABLE 146. CRESCENT PHARMA LIMITED: COMPANY SNAPSHOT
  • TABLE 147. CRESCENT PHARMA LIMITED: PRODUCT SEGMENTS
  • TABLE 148. CRESCENT PHARMA LIMITED: PRODUCT PORTFOLIO
  • TABLE 149. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 150. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 151. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 152. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 153. MERCK & CO., INC.: KEY STRATERGIES
  • TABLE 154. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 155. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 156. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 157. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 158. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. MACROLIDE ANTIBIOTICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MACROLIDE ANTIBIOTICS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN MACROLIDE ANTIBIOTICS MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN MACROLIDE ANTIBIOTICS MARKET (2023-2032)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL MACROLIDE ANTIBIOTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR AZITHROMYCIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR ERYTHROMYCIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR RESPIRATORY TRACT INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR SKIN INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 29. MACROLIDE ANTIBIOTICS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 30. U.S. MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CANADA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. MEXICO MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. GERMANY MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. FRANCE MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. UK MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. ITALY MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SPAIN MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. JAPAN MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. CHINA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. INDIA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. BRAZIL MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 53. COMPETITIVE DASHBOARD
  • FIGURE 54. COMPETITIVE HEATMAP: MACROLIDE ANTIBIOTICS MARKET
  • FIGURE 55. TOP PLAYER POSITIONING, 2022
  • FIGURE 56. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 73. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)